右美托咪定的器官保护作用及其机制概述
Research progress on organ protective effects and mechanisms of dexmedetomidine
- 解放军医学杂志 2023年48卷第11期 页码：1267-1275
- 作者机构：
1.苏州大学附属第一医院麻醉科，江苏苏州 215006
- 作者简介：
丁允莹，硕士研究生，主要从事麻醉与围手术期器官保护方面的研究
彭科，E-mail：pengke0422@163.com
- 基金信息：国家自然科学基金项目(82072130;81873925);江苏省青年重点医学人才项目(QNRC2016741)
DOI：10.11855/j.issn.0577-7402.2532.2023.0530
中图分类号：
扫 描 看 全 文
丁允莹, 嵇富海, 彭科. 右美托咪定的器官保护作用及其机制概述[J]. 解放军医学杂志, 2023, 48(11): 1267-1275.
Ding Yun-Ying,Ji Fu-Hai,Peng Ke.Research progress on organ protective effects and mechanisms of dexmedetomidine[J].Medical Journal of Chinese People′s Liberation Army,2023,48(11):1267-1275.
丁允莹, 嵇富海, 彭科. 右美托咪定的器官保护作用及其机制概述[J]. 解放军医学杂志, 2023, 48(11): 1267-1275. DOI： 10.11855/j.issn.0577-7402.2532.2023.0530.
Ding Yun-Ying,Ji Fu-Hai,Peng Ke.Research progress on organ protective effects and mechanisms of dexmedetomidine[J].Medical Journal of Chinese People′s Liberation Army,2023,48(11):1267-1275. DOI： 10.11855/j.issn.0577-7402.2532.2023.0530.
摘要
右美托咪定作为一种高选择性α,2,肾上腺素能受体激动剂，具有抗交感、镇静、镇痛、抗焦虑作用，且对呼吸影响轻微，近年来已在临床麻醉、围手术期治疗、重症监护领域得到广泛应用。器官功能保护是麻醉和围手术期医学的重要关注点，对于减少并发症、改善短期和长期预后具有重要临床意义。越来越多的基础研究和临床证据显示，右美托咪定对心、脑、肺、肾、肝及胃肠道等重要脏器具有保护作用，其机制可能与抗炎、抗氧化应激、抗凋亡、调节自噬等有关。本文对右美托咪定的器官保护作用及其机制进展进行阐述，以加深临床医师对个体化原则的应用，在发挥右美托咪定器官保护作用的同时避免增加低血压、心动过缓等不良反应，并进一步开展设计严谨的临床研究与深入的机制探索，以指导临床上以最优方式应用右美托咪定，更好地保护围手术期患者的器官功能。
Abstract
Dexmedetomidine is a highly selective α,2, adrenergic receptor agonist, exerting anti-sympathetic, sedative, analgesic and anti-anxiety effects, with minimal impact on respiration. In recent years, dexmedetomidine has been widely used in clinical anesthesia, perioperative treatment, and intensive care. Organ-protection is an important focus of anesthesia and perioperative medicine, with clinical significance in reducing complications and improving short- and long-term outcomes. Increasing clinical evidence and basic research have shown that the application of dexmedetomidine could protect the heart, brain, lung, kidney, liver, gastrointestinal tract and other important organs. The mechanism may be related to dexmedetomidine's effects of anti-inflammation, anti-oxidation, anti-apoptosis, and autophagy regulation. From our perspectives, clinical use should follow the principle of individualization, and the dose should be adjusted in time according to patients' responses, so as to avoid adverse reactions such as hypotension and bradycardia while protecting the organs. Moreover, more strictly designed clinical studies and in-depth mechanistic investigations are needed for the optimal dexmedetomidine therapy and better organ protection during the perioperative course. In order to facilitate better understanding of clinicians, this paper reviews the organ-protective effects and underlying mechanisms of dexmedetomidine.
关键词
右美托咪定器官保护麻醉围手术期
Keywords
dexmedetomidineorgan protectionanesthesiaperioperative period
references
Virtanen R, Savola JM, Saano V, et al. Characterization of the selectivity, specificity and potency of medetomidine as an alpha 2-adrenoceptor agonist[J]. Eur J Pharmacol, 1988, 150(1-2): 9-14.
Weerink MAS, Struys MMRF, Hannivoort LN, et al. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine[J]. Clin Pharmacokinet, 2017, 56(8): 893-913.
Chen XH, Li MM, Huang H, et al. Effect of dexmedetomidine on perioperative anxiety in thoracic surgery patients[J]. Med J Chin PLA, 2022, 47(5): 464-470.
陈小红, 李萌萌, 黄璜, 等. 右美托咪定对胸外科患者围手术期焦虑的影响[J]. 解放军医学杂志, 2022, 47(5): 464-470.
Xu F, Ao HS. Clinical application of dexmedetomidine hydrochloride[J]. Chin Circul J, 2015, 30(4): 401-403.
徐斐, 敖虎山. 盐酸右美托咪定的临床应用[J]. 中国循环杂志, 2015, 30(4): 401-403.
Wang K, Wu M, Xu J, et al. Effects of dexmedetomidine on perioperative stress, inflammation, and immune function: systematic review and meta-analysis[J]. Br J Anaesth, 2019, 123(6): 777-794.
Chen M, Li X, Mu G. Myocardial protective and anti-inflammatory effects of dexmedetomidine in patients undergoing cardiovascular surgery with cardiopulmonary bypass: a systematic review and meta-analysis[J]. J Anesth, 2022, 36(1): 5-16.
Ma J, Chen Q, Li J, et al. Dexmedetomidine-mediated prevention of renal ischemia-reperfusion injury depends in part on cholinergic anti-inflammatory mechanisms[J]. Anesth Analg, 2020, 130(4): 1054-1062.
Han QQ, Li XY, Wang YX. Dexmedetomidine attenuates lipopolysaccharide-induced inflammation through macrophageal IL-10 expression following α7nAchR activation[J]. Int Immunopharmacol, 2022, 109: 108920.
Li J, Chen Q, He X, et al. Dexmedetomidine attenuates lung apoptosis induced by renal ischemia-reperfusion injury through α2AR/PI3K/Akt pathway[J]. J Transl Med, 2018, 16(1): 78.
Wang K, Zhu Y. Dexmedetomidine protects against oxygen-glucose deprivation/reoxygenation injury-induced apoptosis via the p38 MAPK/ERK signalling pathway[J]. J Int Med Res, 2018, 46(2): 675-686.
Zhu Z, Ling X, Zhou H, et al. Dexmedetomidine attenuates cellular injury and apoptosis in H9c2 cardiomyocytes by regulating p-38MAPK and endoplasmic reticulum stress[J]. Drug Des Dev Ther, 2020, 14: 4231-4243.
Deng X, Ye F, Zeng L, et al. Dexmedetomidine mitigates myocardial ischemia/reperfusion-induced mitochondrial apoptosis through targeting lncRNA HCP5[J]. Am J Chin Med, 2022, 50(6): 1529-1551.
Wei Q, Chen J, Xiao F, et al. High-dose dexmedetomidine promotes apoptosis in fetal rat hippocampal neurons[J]. Drug Des Dev Ther, 2021, 15: 2433-2444.
Zhang Z, Mu X, Zhou X. Dexmedetomidine alleviates inflammatory response and oxidative stress injury of vascular smooth muscle cell via α2AR/GSK-3β/MKP-1/NRF2 axis in intracranial aneurysm[J]. BMC Pharmacol Toxico, 2022, 23(1): 81.
Choi HI, Kim HJ, Park JS, et al. PGC-1α attenuates hydrogen peroxide-induced apoptotic cell death by upregulating Nrf-2 via GSK3β inactivation mediated by activated p38 in HK-2 cells[J]. Sci Rep, 2017, 7(1): 4319.
Zhao Y, Kong GY, Pei WM, et al. Dexmedetomidine alleviates hepatic injury via the inhibition of oxidative stress and activation of the Nrf2/HO-1 signaling pathway[J]. Eur Cytokine Netw, 2019, 30(3): 88-97.
Chen J, Shen N, Duan X, et al. An investigation of the mechanism of dexmedetomidine in improving postoperative cognitive dysfunction from the perspectives of alleviating neuronal mitochondrial membrane oxidative stress and electrophysiological dysfunction[J]. Exp Ther Med, 2018, 15(2): 2037-2043.
Wang YQ, Xu P, Fan HJ, et al. Research progress in the relationship of autophagy and blood brain barrier[J]. Med J Chin PLA, 2022, 47(5): 518-523.
王俣棋, 徐鹏, 范红结, 等. 细胞自噬与血脑屏障的关系研究进展[J]. 解放军医学杂志, 2022, 47(5): 518-523.
Yu T, Liu D, Gao M, et al. Dexmedetomidine prevents septic myocardial dysfunction in rats via activation of α7nAChR and PI3K/Akt-mediated autophagy[J]. Biomed Pharmacother, 2019, 120: 109231.
Lempiäinen J, Finckenberg P, Mervaala EE, et al. Dexmedetomidine preconditioning ameliorates kidney ischemia-reperfusion injury[J]. Pharmacol Res Perspe, 2014, 2(3): e00045.
Li Y, Qu M, Xing F, et al. The protective mechanism of dexmedetomidine in regulating Atg14L-Beclin1-Vps34 complex against myocardial ischemia-reperfusion injury[J]. J Cardiovasc Transl, 2021, 14(6): 1063-1074.
Zhu Y, Li S, Liu J, et al. Role of JNK signaling pathway in dexmedetomidine post-conditioning-induced reduction of the inflammatory response and autophagy effect of focal cerebral ischemia reperfusion injury in rats[J]. Inflammation, 2019, 42(6): 2181-2191.
Peng K, Shen YP, Ying YY, et al. Perioperative dexmedetomidine and 5-year survival in patients undergoing cardiac surgery[J]. Br J Anaesth, 2021, 127(2): 215-223.
Biccard BM, Goga S, de Beurs J. Dexmedetomidine and cardiac protection for non-cardiac surgery: a meta-analysis of randomised controlled trials[J]. Anaesthesia, 2008, 63(1): 4-14.
Talke P, Chen R, Thomas B, et al. The hemodynamic and adrenergic effects of perioperative dexmedetomidine infusion after vascular surgery[J]. Anesth Analg, 2000, 90(4): 834-839.
Cai Y, Xu H, Yan J, et al. Molecular targets and mechanism of action of dexmedetomidine in treatment of ischemia/reperfusion injury[J]. Mol Med Rep, 2014, 9(5): 1542-1550.
Bunte S, Behmenburg F, Majewski N, et al. Characteristics of dexmedetomidine postconditioning in the field of myocardial ischemia-reperfusion injury[J]. Anesth Analg, 2020, 130(1): 90-98.
Elgebaly AS, Fathy SM, Sallam AA, et al. Cardioprotective effects of propofol-dexmedetomidine in open-heart surgery: A prospective double-blind study[J]. Ann Card Anaesth, 2020, 23(2): 134-141.
Zhang GR, Peng CM, Liu ZZ, et al. The effect of dexmedetomidine on myocardial ischemia/reperfusion injury in patients undergoing cardiac surgery with cardiopulmonary bypass: a meta-analysis[J]. Eur Rev Med Pharmacol Sci, 2021, 25(23): 7409-7417.
Kalisnik JM, Avbelj V, Trobec R, et al. Assessment of cardiac autonomic regulation and ventricular repolarization after off-pump coronary artery bypass grafting[J]. Heart Surg Forum, 2006, 9(3): E661-E667.
Ling X, Zhou H, Ni Y, et al. Does dexmedetomidine have an antiarrhythmic effect on cardiac patients? A meta-analysis of randomized controlled trials[J]. PLoS One, 2018, 13(3): e0193303.
Turan A, Bashour CA, You J, et al. Dexmedetomidine sedation after cardiac surgery decreases atrial arrhythmias[J]. J Clin Anesth, 2014, 26(8): 634-642.
Liu X, Xie G, Zhang K, et al. Dexmedetomidine vs propofol sedation reduces delirium in patients after cardiac surgery: a meta-analysis with trial sequential analysis of randomized controlled trials[J]. J Crit Care, 2017, 38: 190-196.
Turan A, Duncan A, Leung S, et al. Dexmedetomidine for reduction of atrial fibrillation and delirium after cardiac surgery (DECADE): a randomised placebo-controlled trial[J]. Lancet, 2020, 396(10245): 177-185.
Yang YF, Wang H, Song N, et al. Dexmedetomidine attenuates ischemia/reperfusion-induced myocardial inflammation and apoptosis through inhibiting endoplasmic reticulum stress signaling[J]. J Inflamm Res, 2021, 14: 1217-1233.
Zhang Y, Zhao Q, Li X, et al. Dexmedetomidine reversed hypoxia/reoxygenation injury-induced oxidative stress and endoplasmic reticulum stress-dependent apoptosis of cardiomyocytes via SIRT1/CHOP signaling pathway[J]. Mol Cell Biochem, 2021, 476(7): 2803-2812.
Bao N, Tang B. Organ-protective effects and the underlying mechanism of dexmedetomidine[J]. Mediators Inflamm, 2020, 2020: 6136105.
Peng K, Chen WR, Xia F, et al. Dexmedetomidine post-treatment attenuates cardiac ischaemia/reperfusion injury by inhibiting apoptosis through HIF-1α signalling[J]. J Cell Mol Med, 2020, 24(1): 850-861.
Liaquat Z, Xu X, Zilundu PLM, et al. The current role of dexmedetomidine as neuroprotective agent: an updated review[J]. Brain Sci, 2021, 11(7): 846.
Duan X, Coburn M, Rossaint R, et al. Efficacy of perioperative dexmedetomidine on postoperative delirium: systematic review and meta-analysis with trial sequential analysis of randomised controlled trials[J]. Br J Anaesth, 2018, 121(2): 384-397.
Aldecoa C, Bettelli G, Bilotta F, et al. European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium[J]. Eur J Anaesthesiol, 2017, 34(4): 192-214.
Su X, Meng ZT, Wu XH, et al. Dexmedetomidine for prevention of delirium in elderly patients after non-cardiac surgery: a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2016, 388(10054): 1893-1902.
Evered LA, Silbert BS. Postoperative cognitive dysfunction and noncardiac surgery[J]. Anesth Analg, 2018, 127(2): 496-505.
Unchiti K, Leurcharusmee P, Samerchua A, et al. The potential role of dexmedetomidine on neuroprotection and its possible mechanisms: evidence from in vitro and in vivo studies[J]. Eur J Neurosci, 2021, 54(9): 7006-7047.
Brambrink AM, Evers AS, Avidan MS, et al. Isoflurane-induced neuroapoptosis in the neonatal rhesus macaque brain[J]. Anesthesiology, 2010, 112(4): 834-841.
Creeley CE, Dikranian KT, Dissen GA, et al. Isoflurane-induced apoptosis of neurons and oligodendrocytes in the fetal rhesus macaque brain[J]. Anesthesiology, 2014, 120(3): 626-638.
Perez-Zoghbi JF, Zhu W, Grafe MR, et al. Dexmedetomidine-mediated neuroprotection against sevoflurane-induced neurotoxicity extends to several brain regions in neonatal rats[J]. Br J Anaesth, 2017, 119(3): 506-516.
Sanders RD, Xu J, Shu Y, et al. Dexmedetomidine attenuates isoflurane-induced neurocognitive impairment in neonatal rats[J]. Anesthesiology, 2009, 110(5): 1077-1085.
Meng F, Yu W, Duan W, et al. Dexmedetomidine attenuates LPS-mediated BV2 microglia cells inflammation via inhibition of glycolysis[J]. Fund Clin Pharmacol, 2020, 34(3): 313-320.
Bao Y, Zhu Y, He G, et al. Dexmedetomidine attenuates neuroinflammation in LPS-stimulated BV2 microglia cells through upregulation of miR-340[J]. Drug Des Dev Ther, 2019, 13: 3465-3475.
Zhao S, Wu W, Lin X, et al. Protective effects of dexmedetomidine in vital organ injury: crucial roles of autophagy[J]. Cell Mol Biol Lett, 2022, 27(1): 34.
Jiang YX, Zhan MJ, Xing ZQ, et al. Dexmedetomidine alleviates LPS-induced acute lung injury by α7nAChR mediated TLR4/NF-κB pathway[J]. Med J Chin PLA, 2021, 46(3): 231-237.
姜远旭, 詹美俊, 幸志强, 等. 右美托咪定通过α7nAChR介导的TLR4/NF-κB通路减轻脂多糖诱导的急性肺损伤[J]. 解放军医学杂志, 2021, 46(3): 231-237.
Meng L, Li L, Lu S, et al. The protective effect of dexmedetomidine on LPS-induced acute lung injury through the HMGB1-mediated TLR4/NF-κB and PI3K/Akt/mTOR pathways[J]. Mol Immunol, 2018, 94: 7-17.
Wu CY, Lu YF, Wang ML, et al. Effects of dexmedetomidine infusion on inflammatory responses and injury of lung tidal volume changes during one-lung ventilation in thoracoscopic surgery: a randomized controlled trial[J]. Mediators Inflamm, 2018, 2018: 2575910.
Huang SQ, Zhang J, Zhang XX, et al. Can dexmedetomidine improve arterial oxygenation and intrapulmonary shunt during one-lung ventilation in adults undergoing thoracic surgery? A meta-analysis of randomized, placebo-controlled trials[J]. Chin Med J (Engl), 2017, 130(14): 1707-1714.
Lee SH, Kim N, Lee CY, et al. Effects of dexmedetomidine on oxygenation and lung mechanics in patients with moderate chronic obstructive pulmonary disease undergoing lung cancer surgery: a randomised double-blinded trial[J]. Eur J Anaesthesiol, 2016, 33(4): 275-282.
Shi J, Yu T, Song K, et al. Dexmedetomidine ameliorates endotoxin-induced acute lung injury in vivo and in vitro by preserving mitochondrial dynamic equilibrium through the HIF-1a/HO-1 signaling pathway[J]. Redox Biol, 2021, 41: 101954.
Liu Y, Sheng B, Wang S, et al. Dexmedetomidine prevents acute kidney injury after adult cardiac surgery: a meta-analysis of randomized controlled trials[J]. BMC Anesthesiol, 2018, 18(1): 7.
Liu X, Hu Q, Chen Q, et al. Effect of dexmedetomidine for prevention of acute kidney injury after cardiac surgery: an updated systematic review and meta-analysis[J]. Ren Fail, 2022, 44(1): 1150-1159.
Peng K, Li D, Applegate RL, et al. Effect of dexmedetomidine on cardiac surgery-associated acute kidney injury: a meta-analysis with trial sequential analysis of randomized controlled trials[J]. J Cardiothorac Vasc Anesth, 2020, 34(3): 603-613.
Kim WH, Hur M, Park SK, et al. Pharmacological interventions for protecting renal function after cardiac surgery: a Bayesian network meta-analysis of comparative effectiveness[J]. Anaesthesia, 2018, 73(8): 1019-1031.
Shan XS, Dai HR, Zhao D, et al. Dexmedetomidine reduces acute kidney injury after endovascular aortic repair of Stanford type B aortic dissection: a randomized, double-blind, placebo-controlled pilot study[J]. J Clin Anesth, 2021, 75: 110498.
Shan XS, Hu LK, Wang Y, et al. Effect of perioperative dexmedetomidine on delayed graft function following a donation-after-cardiac-death kidney transplant: a randomized clinical trial[J]. JAMA Netw Open, 2022, 5(6): e2215217.
Loomba RS, Villarreal EG, Dhargalkar J, et al. The effect of dexmedetomidine on renal function after surgery: a systematic review and meta-analysis[J]. J Clin Pharm Ther, 2022, 47(3): 287-297.
Tao WH, Shan XS, Zhang JX, et al. Dexmedetomidine attenuates ferroptosis-mediated renal ischemia/reperfusion injury and inflammation by inhibiting ACSL4 via α2-AR[J]. Front Pharmacol, 2022, 13: 782466.
Wang Z, Wu J, Hu Z, et al. Dexmedetomidine alleviates lipopolysaccharide-induced acute kidney injury by inhibiting p75NTR-mediated oxidative stress and apoptosis[J]. Oxid Med Cell Longev, 2020, 2020: 5454210.
Dickson RP. The microbiome and critical illness[J]. Lancet Respir Med, 2016, 4(1): 59-72.
Sahin T, Begeç Z, Toprak H, et al. The effects of dexmedetomidine on liver ischemia-reperfusion injury in rats[J]. J Surg Res, 2013, 183(1): 385-390.
Huang YQ, Wen RT, Li XT, et al. The protective effect of dexmedetomidine against ischemia-reperfusion injury after hepatectomy: a meta-analysis of randomized controlled trials[J]. Front Pharmacol, 2021, 12: 747911.
Iirola T, Vilo S, Aantaa R, et al. Dexmedetomidine inhibits gastric emptying and oro-caecal transit in healthy volunteers[J]. Br J Anaesth, 2011, 106(4): 522-527.
Behera BK, Misra S, Jena SS, et al. The effect of perioperative dexmedetomidine on postoperative bowel function recovery in adult patients receiving general anesthesia[J]. Minerva Anestesiol, 2022, 88(1-2): 51-61.
Gustafsson UO, Scott MJ, Hubner M, et al. Guidelines for perioperative care in elective colorectal surgery: Enhanced Recovery After Surgery (ERAS) Society recommendations: 2018[J]. World J Surg, 2019, 43(3): 659-695.
Zhang YN, Chang ZN, Liu ZM, et al. Dexmedetomidine alleviates gut-vascular barrier damage and distant hepatic injury following intestinal ischemia/reperfusion injury in mice[J]. Anesth Analg, 2022, 134(2): 419-431.
Zhou L, Li J, Liu X, et al. Dexmedetomidine promotes apoptosis and suppresses proliferation of hepatocellular carcinoma cells via microRNA-130a/EGR1 axis[J]. Cell Death Discov, 2022, 8(1): 31.
Zhang Q, Liu XM, Hu Q, et al. Dexmedetomidine inhibits mitochondria damage and apoptosis of enteric glial cells in experimental intestinal ischemia/reperfusion injury via SIRT3-dependent PINK1/HDAC3/p53 pathway[J]. J Transl Med, 2021, 19(1): 463.
0
浏览量
0
下载量
0
CSCD
0
CNKI被引量
- 网络PDF下载
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies